Shocking exit bonus for a departing chief? Not us, Roche says

Outgoing Roche ($RHHBY) Chairman Franz Humer will get a bonus when he leaves next year, Vice Chairman Andre Hoffman told shareholders. But it will be "completely different" from the $76 million fellow Swiss drugmaker Novartis ($NVS) originally planned to pay ex-chairman Daniel Vasella. Roche stockholders voted 99.6% in favor of the company's compensation plans, days after Swiss voters approved sweeping new restrictions on executive pay. Report

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

Researchers scoured the database where pharma companies disclose payments made to physicians and discovered a troubling trend.